WEST Search History

DATE: Tuesday, June 25, 2002

Set Name side by side	Query	Hit Count	Set Name result set
DB = USI	PT; PLUR=YES; OP=OR		
L6	E-cadherin and snail	1	L6
L5	L3 and "tumor marker"	2	L5
L4	L3 and tumor marker	68153	L4
L3	snail	1262	L3
L2	L1 and "tumor marker"	1	L2
L1	sna	1758	L1

END OF SEARCH HISTORY

Search09806445

S1

S2

S3

s snail and (cancer? or tumor?)

```
Items File
      -----
            5: Biosis Previews(R) 1969-2002/Jun W3
       162 34: SciSearch(R) Cited Ref Sci 1990-2002/Jun W5
        2 35: Dissertation Abs Online 1861-2002/May
        1 65: Inside Conferences 1993-2002/Jun W4
       34 71: ELSEVIER BIOBASE 1994-2002/Jun W4
       73 73: EMBASE 1974-2002/Jun W3
          77: Conference Papers Index 1973-2002/May
        5 94: JICST-EPlus 1985-2002/May W1
       37 98: General Sci Abs/Full-Text 1984-2002/May
        4 135: NewsRx Weekly Reports 1995-2002/Apr W1
       19 144: Pascal 1973-2002/Jun W4
       70 149: TGG Health&Wellness DB(SM) 1976-2002/Jun W3
       51 155: MEDLINE(R) 1966-2002/Jun W4
       13 156: ToxFile 1966-2002/Mar W4
       49 159: Cancerlit 1975-2002/May
        2 162: CAB HEALTH 1983-2002/May
        1 164: Allied & Complementary Medicine 1984-2002/Jun
        4 172: EMBASE Alert 2002/Jun W4
        3 266: FEDRIP 2002/Apr
        4 369: New Scientist 1994-2002/Jun W2
        4 370: Science 1996-1999/Jul W3
       25 399: CA SEARCH(R) 1967-2002/UD=13626
       37 434: SciSearch(R) Cited Ref Sci 1974-1989/Dec
       18 442: AMA Journals 1982-2002/Jun B1
       10 444: New England Journal of Med. 1985-2002/Jun W4
       11 457: The Lancet 1986-2000/Oct W1
SYSTEM:OS - DIALOG OneSearch
 File 5:Biosis Previews(R) 1969-2002/Jun W3
    (c) 2002 BIOSIS
File 34:SciSearch(R) Cited Ref Sci 1990-2002/Jun W5
    (c) 2002 Inst for Sci Info
File 155:MEDLINE(R) 1966-2002/Jun W4
*File 155: Daily alerts are now available. This file has
been reloaded. Accession numbers have changed.
File 159:Cancerlit 1975-2002/May
    (c) format only 2002 Dialog Corporation
*File 159: The file will be reloaded. Accession Numbers will change.
Set Items Description
      337 SNAIL AND (CANCER? OR TUMOR?)
      204 S1 NOT PY=>1999
      17 S2 AND MARKER?
```

```
S4
      13 RD (unique items)
Set
     Items Description
S1
      337 SNAIL AND (CANCER? OR TUMOR?)
S2
      204 S1 NOT PY=>1999
S3
      17 S2 AND MARKER?
S4
      13 RD (unique items)
S5
      160 S1 AND EXPRESS?
S6
      61 S5 NOT PY=>1999
S7
      47 RD (unique items)
Set
    Items Description
S1
     2920 METASTA?(W)POTENTIAL
S2
      48 S1 AND CRITERI?
```

2/9/5 DIALOG(R)File 155:MEDLINE(R)

10642933 20183523 PMID: 10717623

Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience.

Padmore R F; Fowble B; Hoffman J; Rosser C; Hanlon A; Patchefsky A S Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

Cancer (UNITED STATES) Mar 15 2000, 88 (6) p1403-9, ISSN 0008-543X

Journal Code: 0374236

Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Subfile: AIM; INDEX MEDICUS

BACKGROUND: Microinvasive breast carcinoma (MIC) has a good prognosis but specific definitions have varied in the past, making the clinical significance of MIC a subject of debate. METHODS: Microscopic slides of 59 cases of breast carcinoma originally diagnosed as MIC were reviewed retrospectively. Histologic parameters were correlated with clinical findings and outcome to define diagnostic criteria better. RESULTS: On review, the 59 cases were recategorized as follows: pure DCIS (N = 16), DCIS with foci equivocal for microinvasion (N = 7), DCIS with > or =1 focus of microinvasion (N = 11), T1 invasive carcinomas with > or =90% DCIS (N = 18), and T1 tumors with <90% DCIS (N = 7). The MIC cases in the current study averaged 3 separate foci of early infiltration outside the basement membrane, each one not >1.0 mm. The mean follow-up was 95 months. Six patients (10%) had only local recurrence: 1 case each in patients with equivocal microinvasion, microinvasion, and T1 tumors with <90% DCIS and 3 cases among the patients with T1 tumors with > or = 90% DCIS. Four

patients, all with T1 tumors with > or =90% DCIS, had distant failure (7%). In the MIC group, only one patient developed a local recurrence after breast conservation. No patient had axillary lymph node metastasis. For the entire series, factors associated with local recurrence were younger age, breast conservation versus mastectomy, and close surgical margins. The only factor associated with distant failure was the size of the DCIS component. Seven patients with T1 tumors with > or =90% DCIS experienced local or distant failure and 5 of these (71%) developed progressive disease or died of disease. All other patients who developed a recurrence were disease free at last follow-up. In a retrospective series, poorer outcome in carcinomas with > or =90% DCIS may be related to the greater likelihood of missed larger areas of invasive carcinoma. Therefore, meticulous and extensive sampling of these carcinomas is required. CONCLUSIONS: MIC as defined has a good prognosis. It has a different biology than T1 invasive carcinoma with > or =90% DCIS, which may progress and cause death. Large tumors with multiple foci of microinvasion may have metastatic potential. Copyright 2000 American Cancer Society.

2/9/7
DIALOG(R)File 155:MEDLINE(R)

10305754 99293465 PMID: 10365131

The histopathological heterogeneity of small renal cell carcinoma.

Wunderlich H; Schlichter A; Kosmehl H; Schubert J

Department of Urology, Friedrich-Schiller-University Jena, Germany.

Anticancer research (GREECE) Mar-Apr 1999, 19 (2C) p1497-500, ISSN

0250-7005 Journal Code: 8102988 Document type: Journal Article

Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed
Subfile: INDEX MEDICUS

BACKGROUND: Renal tumors resembling renal cell carcinoma but less than 3 cm in diameter historically have been regarded as adenomas because of their low frequency of metastases. However, this concept has been challenged, and it seems that all of these lesions should be considered carcinomas. Thus, the extent of radical surgery of these findings have been reconsidered, in view of the uncertainty regarding their malignant or benign nature.

MATERIALS AND METHODS: 107 tumors 40 mm or less in diameter were accordingly divided into three groups and clinico- and histopathological criteria were correlated: group 1: 20 mm or less (n = 33), group 2: 21-30 mm (n = 28) and group 3: 31-40 mm (n = 43). RESULTS: Both lymph node metastases and distant metastases were well correlated with tumor size.

Grade 1 renal cell carcinomas decreased in their frequency with an increasing tumor diameter. In grade 3 carcinomas an opposite result was found. With an increase of tumor size the frequency of venous involvement

increases as well. Significant more multifocal malignant renal cell carcinoma were seen in renal cell carcinoma between 21-40 mm compared to tumors 20 mm or less in diameter. CONCLUSION: Although the metastatic potential and the biology of small renal tumors are not yet known, it seems that nephron-sparing surgery in patients with renal cell carcinoma more than 20 mm in diameter should only be performed when there is an absolute indication, such as bilateral carcinomas, single kidney or renal failure. The problem is that a long-term follow-up study is mandatory to justify partial nephrectomy as a nephron-sparing operation for renal cell carcinoma more than 20 mm in patients with normal function of the contralateral kidney.